New combo aims to boost remission in leukemia
NCT ID NCT02514083
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a complete response after 24 weeks and how many stop treatment due to side effects. Ibrutinib is continued long-term unless the disease worsens or side effects become intolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (Imbruvica) and fludarabine (Fludara)
What this could lead to
If successful, this combination could offer a more effective initial treatment for CLL/SLL, potentially leading to higher remission rates without long-term chemotherapy.
What could go wrong
This is a small, early-phase pilot study with only 29 participants. The combination may cause intolerable side effects, and results may not apply to all patients. Ibrutinib is taken indefinitely, so it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States